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Abstract
Objective: To examine the use of vitamin D supplements during infancy among
the participants in an international infant feeding trial.
Design: Longitudinal study.
Setting: Information about vitamin D supplementation was collected through a
validated FFQ at the age of 2 weeks and monthly between the ages of 1 month
and 6 months.
Subjects: Infants (n 2159) with a biological family member affected by type 1
diabetes and with increased human leucocyte antigen-conferred susceptibility to
type 1 diabetes from twelve European countries, the USA, Canada and Australia.
Results: Daily use of vitamin D supplements was common during the first 6
months of life in Northern and Central Europe (.80% of the infants), with
somewhat lower rates observed in Southern Europe (.60%). In Canada, vitamin
D supplementation was more common among exclusively breast-fed than other
infants (e.g. 71% v. 44% at 6 months of age). Less than 2% of infants in the USA
and Australia received any vitamin D supplementation. Higher gestational age,
older maternal age and longer maternal education were study-wide associated
with greater use of vitamin D supplements.
Conclusions: Most of the infants received vitamin D supplements during the first
6 months of life in the European countries, whereas in Canada only half and in
the USA and Australia very few were given supplementation.
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Some developed countries(1–4) have reported a resur-
gence of vitamin D deficiency and rickets in children and
infants, in spite of national recommendations for vitamin
D supplementation in infancy. The content of vitamin D
in breast milk is very low(5,6) and thus exclusively breast-fed
children have greater risk of developing vitamin D
deficiency than children receiving infant formula(7).
Adequacy of prenatal vitamin D transfer depends on
maternal vitamin D stores, which have been shown to be
inadequate in many countries(8). Natural food sources of
vitamin D are few, the most common being egg yolk
and fish(9). Vitamin D fortification of foods has becomey See Appendix for a full list of the TRIGR Investigators.
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common in various countries. Typical fortified food items
are milk, margarine, juices and breakfast cereals(10). Also,
infant formulas are fortified with vitamin D. Recommenda-
tions given for the use of vitamin D supplements during
infancy are currently quite uniform in different countries(11–13),
while compliance with these recommendations varies
widely(14–16). There is a lack of internationally compar-
able data on vitamin D supplement use.
The Trial to Reduce IDDM in the Genetically at Risk
(TRIGR; IDDM5 insulin-dependent diabetes mellitus) is
an international, randomized, double-blinded study test-
ing the hypothesis whether weaning to an extensively
hydrolysed infant formula reduces the risk of developing
type 1 diabetes (T1D) in children with increased genetic
disease susceptibility(17). The TRIGR prospective nutrition
questionnaires provide a unique opportunity to compare
information on vitamin D supplement use in different
countries. Through that study we aimed to determine
how vitamin D supplements were used in infancy in the
TRIGR countries and to assess adherence with national
recommendations. Further, we assessed how infant
feeding, sociodemographic and perinatal factors, region
and maternal T1D were related to the use of vitamin D
supplements.
Experimental methods
Study population
Newborn infants with a biological first-degree relative
affected by T1D as defined by the WHO were invited into
the study. The families were recruited when the mother
was in late pregnancy (gestational age 35 weeks or more)
or immediately after the delivery. Human leucocyte
antigen (HLA) genotyping was performed from cord
blood or from a blood sample obtained before the age of
8 d. Infants with increased HLA-conferred susceptibility to
T1D were eligible to participate in the study. Altogether
2159 infants from twelve countries in Europe and from
the USA, Canada and Australia, born between May 2002
and February 2007, were included in the TRIGR study. Of
these, 1095 were born to women with diabetes and 1064
to unaffected women. The TRIGR countries have been
divided into seven regions: Northern Europe (Finland and
Sweden, n 521); Central Europe I (Czech Republic,
Estonia, Hungary and Poland, n 317; i.e. transition
economies); Central Europe II (Germany, Luxembourg,
the Netherlands and Switzerland, n 184); Southern
Europe (Italy and Spain, n 114); the USA (n 393); Canada
(n 528); and Australia (n 102). The study was conducted
according to the guidelines laid down in the Declaration
of Helsinki. The ethical committee of each site approved
the study and signed consent was obtained from the
parents or legal guardians of the infant.
Exclusion criteria included multiple gestation, an older
sibling already participating in TRIGR, recognizable
severe illness, gestational age ,35 weeks, age of the
infant more than 7 d at randomization, or no HLA sample
drawn before the age of 8 d. Breast-feeding was
encouraged. Infants were randomized to receive either a
regular cow’s milk-based infant formula or an extensively
hydrolysed infant formula (NutramigenR ; Mead Johnson,
Evansville, IN, USA) upon weaning from breast milk in
the first 6–8 months of life. If mother’s own breast milk or
banked breast milk was not available before randomiza-
tion, these infants were given Nutramigen in order to
avoid exposure to intact cow’s milk proteins. Those
infants who had received any infant formula other than
Nutramigen prior to randomization were excluded.
Finally, families having any other reasons (e.g. religious,
cultural, unwillingness) to refuse feeding the infant with
cow’s milk-based products were excluded. Study for-
mulas were enriched with vitamin D. The study did not
interfere with the standard feeding practices of the infants
other than the avoidance of non-study formulas and
foods containing cow’s milk or beef.
Dietary interviews
Information on infant feeding was acquired from the
family through standardized dietary interviews. Data
on vitamin D supplement use were collected with a
validated(18) FFQ at several time points during the first
year of life. The content of vitamin D in the supplements
was not inquired and therefore the amount of supple-
mental vitamin D could not be calculated. In the present
study, vitamin D supplementation refers to the use of
vitamin D as supplements and does not include the intake
of vitamin D from infant formulas or other foods. Mothers
were interviewed by a study nurse or dietitian by tele-
phone when the child was 2 weeks, 1 month, 2 months,
4 months and 5 months old, and at study centre visits at
the ages of 3 and 6 months.
Of randomized families, 99?6% (varied between 98?3
and 100% in the different regions) participated in the first
interview (at the age of 2 weeks) and 98?8% (varied
between 98?1 and 100% in the different regions) of them
answered the question concerning vitamin D supplement
use. Of randomized families, 98?8% (varied between 95?6
and 100% in the different regions) participated in the
study visit at the age of 6 months and 95?0% (varied
between 92?4 and 98?3% in the different regions) of them
answered the vitamin D supplement question.
Statistics
The use of vitamin D supplements was divided into two
categories: (i) any use and (ii) daily use. The daily use
was defined as 4–7 times/week. The use of vitamin D
supplements was recorded at each dietary interview.
The associations of sociodemographic and perinatal fac-
tors with the use of vitamin D supplements at 6 months
of age were analysed using univariate and multivariate
logistic regression analyses. The results are shown as
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odds ratios and 95% confidence intervals. All statistical
tests were two-sided, at a significance level of P,0?05,
and performed using the SAS statistical software package
version 9?1.
Results
Vitamin D supplementation from 2 weeks to 6 months of
age varied significantly by region (Table 1). Most of the
infants who received vitamin D supplements were given
them daily. From 2 weeks up to 6 months of age, more
than 80% of the infants received vitamin D supplements
in Northern (Finland and Sweden) and Central Europe
(Czech Republic, Estonia, Hungary, Poland, Germany,
Luxembourg, the Netherlands and Switzerland), over
60% in Southern Europe (Italy and Spain), and approxi-
mately 50% in Canada. Less than 2% of infants in the USA
and Australia received vitamin D supplements between
the age of 2 weeks and 6 months (Table 1).
There were no significant differences in the vitamin D
supplementation of infants between mothers with
and without T1D (see online supplementary material,
Supplemental Table 1). When vitamin D supplement use
was examined in relation to exclusive breast-feeding,
differences between those exclusively breast-fed up to at
least 5 months and the others were notable only for
Canada, with exclusively breast-fed infants receiving
more supplementation than the other infants (Table 2).
Maternal T1D, caesarean section and living in Central
Europe II, Southern Europe and Canada were associated
with less frequent use of vitamin D supplements, whereas
higher gestational age was associated with more frequent
use of vitamin D supplements at the age of 6 months in
univariate analysis (Table 3). When all the factors asso-
ciated with the use of vitamin D supplementation at
6 months of age were considered simultaneously in a
multivariate analysis, higher gestational age, older maternal
age and longer maternal education were associated with
more frequent use of vitamin D supplements (Table 3).
Infants living in Central Europe II, Southern Europe and
Canada were less likely to get vitamin D supplementation
when compared with those living in Northern Europe. The
USA and Australia were not included in the analysis as the
use of vitamin D supplements in those regions was very low.
Discussion
In the TRIGR study, the use of vitamin D supplements
during the first 6 months of life varied by region with
more than 80% of the infants living in Northern and
Central Europe receiving supplementation, over 60% in
Southern Europe and only half in Canada. The use of
vitamin D supplements was extremely rare in the USA
and Australia, where very few infants received any sup-
plementation during the first 6 months of life. Higher
gestational age and maternal age and longer education
were associated with more frequent use of vitamin D
supplements. Maternal T1D was not associated with
vitamin D supplement use. Considerable difference in
supplementation by breast-feeding status was only seen
Table 1 Use of vitamin D supplementation in different regions according to child age: TRIGR (Trial to Reduce IDDM in the Genetically at
Risk) study, 2002–2007
Region-
0–2 weeks
(%)
2 weeks–1 month
(%)
1–2 months
(%)
2–3 months
(%)
3–4 months
(%)
4–5 months
(%)
5–6 months
(%)
Northern Europe (n 521)
Any use-
-
23?6 84?3 94?2 97?3 97?7 98?1 97?3
Daily usey 2?8 79?7 92?4 94?7 95?0 96?0 96?0
Central Europe I (n 317)
Any use 46?6 91?6 96?0 97?3 96?3 97?3 97?3
Daily use 22?7 84?4 94?7 95?7 95?7 97?0 95?6
Central Europe II (n 184)
Any use 52?7 80?8 87?4 87?2 84?4 84?3 82?6
Daily use 41?3 74?7 85?2 83?9 80?0 82?0 79?2
Southern Europe (n 114)
Any use 30?9 62?3 67?9 68?9 71?8 73?5 77?5
Daily use 23?6 60?4 67?0 67?0 70?9 72?6 75?5
USA (n 393)
Any use 0?3 0?8 1?0 1?0 1?6 1?6 1?6
Daily use 0?3 0?5 1?0 0?8 1?0 1?0 0?8
Canada (n 528)
Any use 30?8 49?8 55?0 55?0 53?3 47?7 46?0
Daily use 22?1 42?6 47?5 47?6 45?3 40?5 37?3
Australia (n 102)
Any use 1?0 0?0 0?0 1?0 0?0 1?0 1?0
Daily use 1?0 0?0 0?0 1?0 0?0 1?0 1?0
IDDM, insulin-dependent diabetes mellitus.
-The following regions were included: Northern Europe (Finland and Sweden); Central Europe I (Czech Republic, Estonia, Hungary and Poland; transition
economies); Central Europe II (Germany, Luxembourg, the Netherlands and Switzerland); Southern Europe (Italy and Spain); the USA; Canada; and Australia.
-
-
Use of vitamin D supplements in any frequency.
yUse of vitamin D supplements 4–7 times/week.
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in Canada, where exclusively breast-fed infants received
more supplementation.
The present study provides valuable comparative
information about vitamin D supplement use in infancy
from fifteen countries on three continents. The informa-
tion on vitamin D supplementation was acquired by
an FFQ which was validated against two 48 h recall
interviews(18). In the validation study, the agreement of
the two methods for vitamin D supplementation was
shown to be moderate.
Limitations of the present study are that we did not
assess either the dosage of vitamin D supplementation
nor vitamin D intake from food. Nor had we an oppor-
tunity to measure vitamin D from the peripheral circula-
tion. We were not able to collect data regarding vitamin D
supplement use after the age of 6 months. The general-
izability of the findings is limited because the study sub-
jects represent a select group of children as they have an
increased HLA-conferred susceptibility to T1D as well as a
family member affected by T1D. The use of vitamin D
supplements may be more frequent in the present risk
group since vitamin D intake has been associated with
decreased risk of T1D(19).
At the time of the dietary data collection in the TRIGR
study (from 2002 to 2007), several of the countries
involved in TRIGR had given dietary recommendations
for vitamin D supplementation in infants: Sweden and
Switzerland recommended a daily supplementation of
10mg(20,21); Finland and Estonia from 5 to 10mg
depending on breast-feeding status or amount of infant
formula consumed(22,23); Germany 10mg(24); the Nether-
lands 5mg(25); and Canada 10mg until the intake from
other sources reached that level(13). In the USA, vitamin D
supplements were previously recommended only for
those breast-fed infants not exposed to adequate sunlight
and/or whose mothers were vitamin D-deficient(26). From
2003 onwards, a daily supplementation of 5mg was
recommended in the USA unless a certain amount of
fortified infant formula or milk was consumed(27), and in
2008, the recommended dosage for supplementation was
doubled to 10mg(28). Also Finland(12), Estonia(29) and the
Netherlands(25) have increased their recommendation for
vitamin D supplementation to 10mg, and Poland(30),
Italy(31) and Spain(32) have given a recommendation of
10mg daily depending on breast-feeding status or amount
of infant formula consumed. In the Czech Republic,
the recommended dose for vitamin D supplementation
is currently 12?5mg/d(33) and in Hungary 10mg(34). In
Australia, vitamin D supplements are recommended only
for specific infant groups with very little sun exposure
due to dark skin and/or children with veiled mothers(35).
With the exception of Australia, the overall recommended
amounts of supplementation are now very similar during
the first year of life in these countries and also the dif-
ferences in the recommended age at introduction and end
of supplementation are minor. The European Society forT
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Pediatric Endocrinology Bone Club recommends that all
breast-fed infants should receive 10mg of supplemental
vitamin D daily from birth until they are receiving the
same amount of vitamin D daily from their diet(11).
In the current study, the majority of the European
children received vitamin D supplements. Almost all the
infants (96%) in Northern Europe (Finland and Sweden)
were provided vitamin D supplementation daily at the
age of 6 months. In an earlier Finnish cohort study, the
proportion of children receiving vitamin D supplements
was slightly lower: 91% of infants were given supple-
ments at 6 months of age(16). In a large Swedish cohort,
99% of the infants had received vitamin D supplements
during the first year of life(36). In our survey, 96% of
infants were receiving vitamin D supplementation daily
at the age of 6 months in Central Europe I countries
(transition economies), which include Czech Republic,
Estonia, Hungary and Poland. In a previous Polish study,
82% of infants received regular and 14% occasional
vitamin D supplementation at the age of 6 months(37). In
the Central Europe II countries (Germany, Luxembourg,
the Netherlands and Switzerland) 79% of the infants were
given vitamin D supplements daily at the age of 6 months
and 76% of infants in Southern Europe (Italy and Spain).
In an earlier Swiss study, only 64% of infants aged
0–9 months had been given vitamin D supplements
within the preceding 24 h(38). In a Canadian survey the
supplementation rate was higher in 2010 than in our
study: 80% of infants were supplemented with vitamin D
at 2 months of age(39). In the USA, a low use of vitamin D
supplements during infancy has also been reported in
previous studies, being only 4–16% during the first 10
months of life in 2005–2008(14,15). It is possible that the
low rates of supplementation observed in the US TRIGR
population are partly due to the fact that the American
Academy of Pediatrics recommendation for vitamin D
supplementation was introduced only in 2003, after the
TRIGR intervention had started. The lack of vitamin D
recommendations for the general population in Australia
is reflected in the results of the present study and it is
likely that the children participating in TRIGR did not
belong to those specific groups for whom supplementa-
tion has been recommended.
Even though exclusively breast-fed children have
greater risk of developing vitamin D deficiency than
children receiving infant formula (7), it was observed in a
recent Canadian report that also those infants consuming
both breast milk and infant formula and those consuming
only infant formula represented groups at risk of not
meeting the recommended 10mg of vitamin D daily(40). In
a study from the USA it was observed that most (81–98%
during the first 10 months of life) exclusively formula-fed
infants met the 2003 American Academy of Pediatrics
recommendation (5mg vitamin D/d) that was applicable
during the data collection, but only 20–37% would have
met the current recommendation of 10mg/d(14). Among
infants fed both breast milk and infant formula, only
around one-third met the target of 5mg/d and less than
15% would have met the current recommendation. In
most TRIGR regions, there were no significant differences
in vitamin D supplementation between infants exclu-
sively breast-fed for at least 5 months and those who were
not. Canada was an exception in this respect; supplement
use was more common in the exclusively breast-fed
group. Higher frequencies of use compared with the
present study but similar difference by breast-feeding
status was seen in a report from Canada where 98% of
exclusively breast-fed and 88% of infants consuming both
breast milk and infant formula had received vitamin D
supplementation at some point during the first 6 months
Table 3 Risk for the use of vitamin D supplements according to sociodemographic, perinatal and other background factors at 6 months of
age: TRIGR (Trial to Reduce IDDM in the Genetically at Risk) study, 2002–2007
OR 95 % CI P value Adjusted- OR 95 % CI P value
Age of mother (years) 1?00 0?98, 1?03 0?73 1?04 1?00, 1?08 0?04*
Maternal education (years) 1?03 0?99, 1?07 0?17 1?07 1?00, 1?14 0?04*
Paternal education (years) 1?03 0?99, 1?07 0?17 1?06 1?00, 1?12 0?07
Maternal type 1 diabetes, yes v. no 0?64 0?50, 0?81 ,0?001* 1?14 0?78, 1?68 0?50
Gestational age (weeks) 1?21 1?13, 1?31 ,0?001* 1?17 1?03, 1?32 0?01*
Male v. female sex of the child 1?05 0?82, 1?33 0?71 0?88 0?64, 1?20 0?42
Caesarean section v. other mode of birth 0?78 0?61, 0?99 0?04* 0?84 0?60, 1?18 0?31
Ponderal index (kg/m3) 1?01 0?84, 1?22 0?90 0?91 0?72, 1?17 0?47
Region-
-
Northern Europe (reference) 1?00 – – 1?00 – –
Central Europe I 1?01 0?41, 2?46 0?99 1?22 0?47, 3?17 0?68
Central Europe II 0?13 0?07, 0?26 ,0?001* 0?11 0?05, 0?23 ,0?001*
Southern Europe 0?10 0?05, 0?20 ,0?001* 0?11 0?05, 0?24 ,0?001*
Canada 0?02 0?01, 0?04 ,0?001* 0?02 0?01, 0?04 ,0?001*
IDDM, insulin-dependent diabetes mellitus.
*P, 0?05.
-Adjusted for all the variables in the table.
-
-
The following regions were included: Northern Europe (Finland and Sweden); Central Europe I (Czech Republic, Estonia, Hungary and Poland; transition
economies); Central Europe II (Germany, Luxembourg, the Netherlands and Switzerland); Southern Europe (Italy and Spain); and Canada. The USA and
Australia were not included in the analysis as the use of vitamin D supplements in those regions was very low (Tables 1 and 2; online supplementary material,
Supplemental Table 1).
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of life in 2008(40). None of the formula-fed infants had
been supplemented with vitamin D. In 2010 in another
Canadian study, the supplementation rate of infants
receiving only breast milk at 2 months of age was 91%
while the corresponding figures for infants receiving both
breast milk and infant formula or only infant formula
were 79% and 20%, respectively(39). Also, in the USA
differences in vitamin D supplementation of infants fed
only breast milk (5–13% received supplementation),
infants consuming both breast milk and infant formula
(4–11% received supplementation) and infants consuming
only infant formula (1–4% received supplementation)
during the first 10 months of life were observed over the
time period 2005–2007(14).
Some sociodemographic factors have been associated
with the use of vitamin D supplements. Mothers who are
younger have been reported to be less likely to give
vitamin D supplements to their infants(16,38); this was also
seen in our study. Having more than one child in the
family may be associated with less use of vitamin D
supplements(16,38). Higher maternal education was asso-
ciated with more frequent use of vitamin D supplements
in the current study as has been reported before(40,41).
Vitamin D is particularly important for the skeleton
because it is needed for Ca absorption from the intestine.
Insufficient vitamin D intake causes rickets in children
and osteomalacia in adults. Vitamin D supplementation in
infancy has also been associated with reduced risk of
T1D(19). There is also some evidence that vitamin D
deficiency is associated with increased risk of cardiovas-
cular and autoimmune diseases in adults and lower
respiratory infections in children(42). The main natural
source of vitamin D is the synthesis in the skin induced by
UV radiation from the sun(9). With minimal sun exposure,
for example at northern latitudes, or due to protective
clothing or sunscreen, other sources of vitamin D are
required. Because the intake of vitamin D from food is
inadequate for most infants, supplementation is necessary.
It is clear that new protocols and strategies are needed in
some regions to ensure that families get enough information
on the importance of adequate vitamin D intake, especially
in infancy and childhood. Re-education about the impor-
tance of supplementation is essential as families tend to stop
using supplements over time(16).
Conclusion
The importance of adequate vitamin D intake in infancy is
well known and supported by the current recommenda-
tions for use of vitamin D supplements. In the present
study, the recommendations regarding vitamin D sup-
plementation were quite well followed during the first
6 months of life in European countries and to some
extent in Canada. The use of vitamin D supplements was
conspicuously low in the USA and Australia. Due to
increasing concern regarding the high prevalence of
vitamin D deficiency in childhood, and especially in
breast-fed infants, action is needed to train health-care
personnel and develop strategies to inform families about
the importance of adequate intake of vitamin D in
infancy, particularly in those exclusively breast-fed.
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CZE05 - Ceske Budejovice - Hospital Ceske
Budejovice
Tomsikova Zdenka Local Investigator
CZE06 - Plzen - Faculty Hospital Plzen Krckova Petra Local Investigator
CZE07 - Zlin - Hospital of Bata Gogelova Pavla Local Investigator
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Italy ITA01 - Rome - University Campus Bio-Medico of Khazrai Yeganeh Manon Local Coordinator
Rome Maddaloni Ernesto Local Coordinator
Pozzilli Paolo National Investigator
SAR01 - Cagliari - St. Michele Hospital Mannu Carla Local Coordinator
Songini Marco National Investigator
Luxembourg LUX01 - Luxembourg - Centre Hospitalier de de Beaufort Carine National Investigator
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USA04 - Los Angeles - Mattel Children’s Hospital of Devaskar Uday Local Investigator
UCLA Horowitz Heather Coordinator/Dietitian
Rogers Lisa Coordinator/Dietitian
USA05 - Ponce - Ponce School of Medicine Colon Roxana Coordinator
Frazer Teresa Co-Investigator
Torres Jose Local Investigator
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Greenberg Ellen Coordinator
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Schachner Holly Co-Investigator
Softness Barney Co-Investigator
Laboratories HLA-typing Laboratory - Turku - Finland Ilonen Jorma Head of HLA-typing Laboratory
HLA-typing Laboratory - Pittsburgh - PA - USA Trucco Massimo Head of HLA-typing Laboratory
Nichol Lynn Chief Technician
Cow’s Milk Antibody Laboratory - Helsinki - Finland Savilahti Erkki Head of Cow’s Milk Antibody Laboratory
Autoantibody Laboratory - Helsinki - Finland Ha¨rko¨nen Taina Co-Investigator
Knip Mikael Head of Antibody Laboratory
T-Cell Laboratory - Helsinki - Finland Vaarala Outi Head of T-Cell Laboratory
Luopaja¨rvi Kristiina Co-Investigator
T-Cell Laboratory - Toronto - ON - Canada Dosch Hans-Michael Head of T-Cell Laboratory
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